Clinical trials: Foot Infection Fungal
Tinea Pedis
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
This is an open-label, single-dose, dose escalating evaluation of the safety and tolerability of three dose levels of DBI-001 in patients with Tinea pedis.
- Trial name
- NCT04152226
- Testing
- Janthinobacterium lividum
- Where
- Dominican Republic
- Volunteers
- 12 people
- Sponsor
- DermBiont, Inc.
Tinea Pedis
Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
The purpose of this study is to evaluate the efficacy and safety of NAFT-600, applied once daily for 2 weeks, when compared to placebo for 2 weeks in the treatment of subjects with tinea pedis.
- Trial name
- NAFT-600 (NCT01289015)
- Testing
- NAFT-600 ( naftin 2 % gel )
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 855 people
- Sponsor
- Merz North America, Inc.
Foot Fungus, Tinea
Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
A prospective, open, post-market study that will enroll male and female subjects diagnosed with foot fungus and at least one of the following conditions: heel cracks, calluses and/or dry feet.
- Conditions
- Foot Fungus, Tinea, Tinea Pedis, Mycoses
- Trial name
- NCT04265521
- Testing
- Biocool Footcare
- Where
- 2 sites in Sweden
- Volunteers
- 25 people
- Sponsor
- Biocool AB
Tinea Pedis
SB208 for the Treatment of Tinea Pedis
This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in non immunocompromised adult subjects with interdigital tinea pedis.
- Trial name
- NCT02860052
- Testing
- SB208 2%, SB208 4%, SB208 16%
- Where
- Dominican Republic
- Volunteers
- 222 people
- Sponsor
- Novan, Inc.
Onychomycosis of Toenails
Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
- Trial name
- NCT01302119
- Testing
- AN2690 Topical Solution, 5%, Solution Vehicle
- Where
- 32 sites in United States, Canada
- Volunteers
- 604 people
- Sponsor
- Pfizer